Deutsche Bank AG Increases Position in biote Corp. (NASDAQ:BTMD)

Deutsche Bank AG raised its holdings in biote Corp. (NASDAQ:BTMD) by 4,987.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 31,441 shares of the company’s stock after purchasing an additional 30,823 shares during the quarter. Deutsche Bank AG owned 0.06% of biote worth $194,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in BTMD. Price T Rowe Associates Inc. MD purchased a new stake in biote in the fourth quarter valued at $67,000. Commonwealth Equity Services LLC acquired a new position in shares of biote in the fourth quarter worth about $68,000. Intech Investment Management LLC acquired a new position in shares of biote in the fourth quarter worth about $71,000. SG Americas Securities LLC acquired a new position in shares of biote in the fourth quarter worth about $76,000. Finally, Thompson Davis & CO. Inc. acquired a new position in shares of biote in the fourth quarter worth about $77,000. 21.68% of the stock is owned by hedge funds and other institutional investors.

biote Stock Performance

Shares of biote stock opened at $3.54 on Tuesday. The firm has a 50-day simple moving average of $3.56 and a two-hundred day simple moving average of $4.74. The company has a market cap of $193.67 million, a P/E ratio of 13.62 and a beta of 1.17. biote Corp. has a fifty-two week low of $3.04 and a fifty-two week high of $8.44.

biote (NASDAQ:BTMD) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.08 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.02. The firm had revenue of $48.99 million during the quarter, compared to the consensus estimate of $47.25 million. biote had a net margin of 5.20% and a negative return on equity of 32.41%. Equities research analysts forecast that biote Corp. will post 0.75 EPS for the current year.

Insider Activity at biote

In other biote news, Director Stephen Mark Cone bought 38,104 shares of the firm’s stock in a transaction on Monday, March 17th. The shares were acquired at an average cost of $3.88 per share, with a total value of $147,843.52. Following the purchase, the director now directly owns 160,829 shares of the company’s stock, valued at $624,016.52. This trade represents a 31.05% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, major shareholder Guines Llc bought 750,000 shares of the firm’s stock in a transaction on Thursday, March 13th. The stock was acquired at an average cost of $3.22 per share, for a total transaction of $2,415,000.00. Following the completion of the purchase, the insider now directly owns 3,820,938 shares in the company, valued at approximately $12,303,420.36. This represents a 24.42% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders have purchased 1,412,080 shares of company stock valued at $4,598,190. 24.00% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Separately, Craig Hallum decreased their price objective on shares of biote from $12.00 to $8.00 and set a “buy” rating for the company in a research report on Thursday, March 13th.

About biote

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.